Barclays analyst Peter Lawson raised the firm’s price target on Relay Therapeutics (RLAY) to $21 from $17 and keeps an Overweight rating on the shares. The firm is positive on Relay’s initial data for zovegalisib in PI3K-mutated vascular malformations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics price target raised to $19 from $14 at H.C. Wainwright
- Relay Therapeutics: Encouraging Zovegalisib Phase 3 Prospects, Strong Cash Runway, and Raised Price Target Support Buy Rating
- Relay Therapeutics price target raised to $17 from $15 at Citizens
- Relay Therapeutics Highlights Positive Zovegalisib ReDiscover Trial Data
- Relay Therapeutics announces data from Phase 1/2 ReDiscover trial